Ikena Oncology, Inc. (NASDAQ:IKNA - Free Report) - Stock analysts at William Blair issued their Q1 2026 EPS estimates for Ikena Oncology in a research note issued on Thursday, May 8th. William Blair analyst M. Phipps forecasts that the company will earn ($0.20) per share for the quarter. The consensus estimate for Ikena Oncology's current full-year earnings is ($0.91) per share. William Blair also issued estimates for Ikena Oncology's Q2 2026 earnings at ($0.18) EPS, Q3 2026 earnings at ($0.18) EPS and Q4 2026 earnings at ($0.19) EPS.
Ikena Oncology (NASDAQ:IKNA - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.03.
Ikena Oncology Price Performance
Shares of Ikena Oncology stock traded down $0.01 during trading hours on Monday, hitting $1.10. The company had a trading volume of 43,015 shares, compared to its average volume of 167,027. Ikena Oncology has a twelve month low of $0.97 and a twelve month high of $1.94. The company has a market cap of $52.84 million, a P/E ratio of -0.89 and a beta of 0.47. The company's 50-day moving average is $1.21 and its two-hundred day moving average is $1.45.
Hedge Funds Weigh In On Ikena Oncology
Several hedge funds have recently made changes to their positions in IKNA. XTX Topco Ltd grew its stake in Ikena Oncology by 350.6% during the 1st quarter. XTX Topco Ltd now owns 56,452 shares of the company's stock worth $72,000 after buying an additional 43,924 shares during the last quarter. BNP Paribas Financial Markets purchased a new stake in Ikena Oncology in the 4th quarter valued at $72,000. Squarepoint Ops LLC purchased a new position in Ikena Oncology during the 4th quarter worth $72,000. Northern Trust Corp grew its position in Ikena Oncology by 19.7% during the 4th quarter. Northern Trust Corp now owns 57,565 shares of the company's stock worth $94,000 after purchasing an additional 9,456 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its stake in Ikena Oncology by 18,244.1% in the fourth quarter. JPMorgan Chase & Co. now owns 155,741 shares of the company's stock valued at $255,000 after purchasing an additional 154,892 shares during the period. Hedge funds and other institutional investors own 75.00% of the company's stock.
Ikena Oncology Company Profile
(
Get Free Report)
Ikena Oncology, Inc operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway.
Featured Stories
Before you consider Ikena Oncology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ikena Oncology wasn't on the list.
While Ikena Oncology currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
